2012-02-28

(WASHINGTON) – The American Society of Hematology (ASH) and the European Hematology Association (EHA) announce the names of 20 early-career hematologists chosen to participate in the 2012 Translational Research Training in Hematology (TRTH) joint program. The TRTH, now in its third year, provides junior researchers from around the world with a unique, yearlong training and mentoring experience with the goal of fostering the next generation of global leaders in the field of translational research.

Modeled after ASH’s successful Clinical Research Training Institute (CRTI), the TRTH program begins with a rigorous one-week training course to be held March 17 to 23, 2012, in Milan, Italy. During the weeklong course, participants will attend didactic and interactive sessions led by TRTH faculty, some of the world’s leading hematology and translational researchers, on translational research methodology and regulatory requirements. Trainees will also participate in small-group sessions with their TRTH peers and faculty to refine individual research proposals and attend informal presentations by leaders in hematology that are designed to illustrate the variety of pathways to a successful career in hematology research through personal experience.

After the initial weeklong course, participants will meet again at the EHA annual congress in June and again at the ASH annual meeting in December to review the progress of their projects.

“As the world of scientific collaboration becomes more global each year, translational researchers need to understand and direct research in both the European and U.S. systems,” said ASH President Armand Keating, MD of the Princess Margaret Hospital in Toronto. “The TRTH program is special in that it not only teaches the basics of research methodology, epidemiology, and biostatistics, but it also allows participants to gain hands-on experience in these disciplines, while at the same time providing a network of peers and mentors that will be a source of support in the years to come.”

The TRTH program is geared toward medical trainees, biomedical trainees, and pharmaceutical doctorate trainees generally within 12 years of receiving their medical degrees or with less than eight years of postdoctoral experience. Trainees must be members of either ASH or EHA.

2012 TRTH Participants 

Jennifer Amengual, MD
New York University
New York, NY

Mattias Carlsten, MD, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Bethesda, MD

Goda Choi, MD, PhD
Academic Medical Center
Amsterdam, the Netherlands

Rita Coutinho, MD
Barts & the London School of Medicine
London, United Kingdom

Kara Davis, MD
Stanford University
Stanford, CA

Stefan Deneberg, MD
Karolinska Institutet
Stockholm, Sweden

Francine Garrett-Bakelman, MD, PhD
Weill Cornell Medical College
New York, NY

Florian Heidel, MD
Otto-von-Guericke University Magdeburg
Magdeburg, Germany

Anna Kalota, PhD
University of Pennsylvania
Philadelphia, PA

Cyrus Khandanpour, MD, PhD
University Clinic of Essen
Essen, Germany

Olivier Kosmider, PharmD, PhD
Cochin Hospital and Cochin Institute
Paris, France

Andrew Lane, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Luca Mazzarella, MD, PhD
European Institute of Oncology
Milan, Italy

Filippo Milano, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

Anjali Mishra, PhD
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Narcis Popescu, PhD
Oklahoma Medical Research Foundation
Oklahoma City, OK

Raajit Rampal, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Nina Rolf, MD, PhD
University of British Columbia
Vancouver, British Columbia, Canada

Jessica Hoell Spitzer, MD
Heinrich Heine University
Düsseldorf, Germany

Huichun Zhan, MD
Columbia University Medical Center
Bronx, NY

To arrange an interview with a TRTH participant, please contact Lindsey Love, ASH Communications Assistant, at 202-552-4925 or llove@hematology.org. 

The American Society of Hematology is the world’s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. The official journal of ASH is Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online.

back to top